0001005201-19-000058.txt : 20190403 0001005201-19-000058.hdr.sgml : 20190403 20190403165646 ACCESSION NUMBER: 0001005201-19-000058 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190402 FILED AS OF DATE: 20190403 DATE AS OF CHANGE: 20190403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bukofzer Stan CENTRAL INDEX KEY: 0001663041 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13111 FILM NUMBER: 19729770 MAIL ADDRESS: STREET 1: C/O OCERA THERAPEUTICS STREET 2: 525 UNIVERSITY AVENUE, SUITE 610 CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Assertio Therapeutics, Inc CENTRAL INDEX KEY: 0001005201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943229046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: (224) 419-7106 MAIL ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 FORMER COMPANY: FORMER CONFORMED NAME: DEPOMED INC DATE OF NAME CHANGE: 19970408 4 1 wf-form4_155432499061392.xml FORM 4 X0306 4 2019-04-02 0 0001005201 Assertio Therapeutics, Inc ASRT 0001663041 Bukofzer Stan ASSERTIO THERAPEUTICS, INC. 100 SOUTH SAUNDERS ROAD, SUITE 300 LAKE FOREST IL 60045 0 1 0 0 SVP, Chf Scitfc & Tech Officer Common Stock 2019-04-02 4 M 0 25370 0 A 30370 D Common Stock 2019-04-02 4 F 0 7434 5.16 D 22936 D Restricted Stock Units 2019-04-02 4 M 0 25370 0 D 2021-04-02 Common Stock 25370.0 65954 D Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. These Restricted Stock Units are scheduled to vest 27.78% on April 2, 2019, 27.78% on April 2, 2020 and 44.44% on April 2, 2021. The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. /s/ Erin R. McQuade, attorney in fact 2019-04-03